Ocaliva is the classic example of a drug that was approved on the basis of its effects on (alleged) surrogate endpoints while in reality its primary effect was to exacerbate the symptoms of the underlying disease.
Add that to management that is incompetent at best and dishonest at worst and here we are today.
News 
Market Data 
Discover 
